These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33235142)

  • 1. Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19.
    DeVine MN; Maxwell S; Haynes AS; MacBrayne CE; Boguniewicz J
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e293-e295. PubMed ID: 33235142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir.
    Gadzińska J; Kuchar E; Matysiak M; Wanke-Rytt M; Kloc M; Kubiak JZ
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e537-e538. PubMed ID: 33885040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
    Saikia B; Tang J; Robinson S; Nichani S; Lawman KB; Katre M; Bandi S
    Pediatr Infect Dis J; 2021 May; 40(5):e194-e196. PubMed ID: 33847299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
    Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
    Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
    Helleberg M; Niemann CU; Moestrup KS; Kirk O; Lebech AM; Lane C; Lundgren J
    J Infect Dis; 2020 Sep; 222(7):1103-1107. PubMed ID: 32702095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Patel PA; Lapp SA; Grubbs G; Edara VV; Rostad CA; Stokes CL; Pauly MG; Anderson EJ; Piantadosi A; Suthar MS; Khurana S; Sabnis HS
    Br J Haematol; 2021 Aug; 194(3):549-553. PubMed ID: 34096051
    [No Abstract]   [Full Text] [Related]  

  • 7. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
    J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
    [No Abstract]   [Full Text] [Related]  

  • 8. Compassionate use of remdesivir in children with COVID-19.
    Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
    Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Barone F; Giacomelli A; Casalini G; Corbellino M; Lai A; Gori A; Antinori S
    J Antimicrob Chemother; 2024 Sep; 79(9):2400-2402. PubMed ID: 39073825
    [No Abstract]   [Full Text] [Related]  

  • 10. Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country.
    Hammad M; Shalaby L; Sidhom I; Sherief N; Abdo I; Soliman S; Madeny Y; Hassan R; Elmeniawy S; Khamis N; Zaki I; Mansour T; El-Ansary MG; Al-Halfawy A; Abouelnaga S; Elhaddad A
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e853-e864. PubMed ID: 34420893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
    Odeti S; Yellepeddi VK
    Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
    [No Abstract]   [Full Text] [Related]  

  • 12. A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments.
    Sanmartin F; Magrini E; Rando E; Del Giacomo P; Dusina A; Matteini E; Carbone A; Puma G; Leanza GM; Frondizi F; Innocenti I; Maiuro G; Liotti FM; Santangelo R; Laurenti L; Cingolani A
    Am J Case Rep; 2024 Jun; 25():e941165. PubMed ID: 38943241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
    Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
    Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
    Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
    J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
    Maruki T; Nomoto H; Iwamoto N; Yamamoto K; Kurokawa M; Iwatsuki-Horimoto K; Yamayoshi S; Suzuki Y; Kawaoka Y; Ohmagari N
    J Infect Chemother; 2024 Aug; 30(8):793-795. PubMed ID: 38242284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Remdesivir in Myasthenia gravis and COVID-19.
    Peters BJ; Rabinstein AA; DuBrock HM
    Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
    Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
    Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
    [No Abstract]   [Full Text] [Related]  

  • 19. Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19.
    Igari H; Sakao S; Ishige T; Saito K; Murata S; Yahaba M; Taniguchi T; Suganami A; Matsushita K; Tamura Y; Suzuki T; Ido E
    Nat Commun; 2024 Apr; 15(1):3604. PubMed ID: 38684722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials.
    Hedskog C; Spinner CD; Protzer U; Hoffmann D; Ko C; Gottlieb RL; Askar M; Roestenberg M; de Vries JJC; Carbo EC; Martin R; Li J; Han D; Rodriguez L; Parvangada A; Perry JK; Ferrer R; Antón A; Andrés C; Casares V; Günthard HF; Huber M; McComsey GA; Sadri N; Aberg JA; van Bakel H; Porter DP
    Viruses; 2024 Mar; 16(4):. PubMed ID: 38675889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.